Tagged with NTU

Taiwan In an important milestone for Taiwan’s biotech industry, Diamond Biofund – one of the territory’s most well-established venture capital (VC) funds – became the first such firm to list on the Taiwan Stock Exchange last month.   Diamond, defines itself as an “evergreen” biotech venture capital fund, meaning that, unlike…

Hong Kong Well established as Asia’s leading financial services and trading hub, Hong Kong is now looking to better position itself as a centre for biotechnology investment and start-ups. However, in a risk-averse investment environment with strong basic research but little tradition of translational science, such a transformation will take time, capital,…

Hong Kong As managing director of the CR-CP Life Science Fund, whose shareholders, CR Group and CP Group, are on the Fortune Global 500 List, Da Liu leads investments in life sciences companies globally, especially those in emerging sectors such as RNA therapeutics and cancer screening. In conversation with PharmaBoardroom, Liu discusses…

Global Based on analysis from Crunchbase, read on for 2021’s largest VC investments into the biotech industry (which topped USD 65 billion last year) and 2021’s busiest biotech lead investors overall.   Made with Visme Infographic Maker   Made with Visme Infographic Maker

UK Oxford Nanopore hogged the UK biotech headlines in 2021, raising GBP 195 million in a single venture capital round – the year’s largest – and scoring a GBP 350 million listing on the London Stock Exchange, according to new data from the UK BioIndustry Association (BIA) and Clarivate. See below…

Turkey In the world’s 18th largest market, recent pricing struggles have pushed some companies to revaluate their investment approach. Multinational organizations are complying with localization policies but are divided between having their own plant or partnering with a local CMO provider – although all of them appear to agree on one…

Turkey Ersin Erfa, CEO of Centurion, a Turkish manufacturer, discusses the company’s high ambitions, R&D capabilities, and their work on a COVID-19 treatment currently in phase II clinical trials. Erfa explains how their work on orphan drugs, innovative generics, vaccines and plasma will help them continue partnering with global companies to…

Singapore Professor Subra Suresh, president of Nanyang Technological University (NTU) and former director of the US National Science Foundation, explains how the university has managed to consistently be among the top academic institutions in the world despite having only three decades of existence, and outlines Singapore’s strengths as an innovation, trade,…

Cell & Gene Therapy The cell and gene therapy market was valued at USD 6 billion in 2017 and is projected to exceed USD 35 billion in value by 2026. Moreover, these therapies stand to redefine medical paradigms by providing treatments for previously incurable diseases and usher in a new era of precise and…

Taiwan Dr James Chih-Hsin Yang, director of National Taiwan University Hospital’s department of oncology, speaks about oncology in Taiwan and the role that the NTU network plays in the island’s oncology space. Dr Yang goes on to share his insights on key trends shaping modern and future cancer treatment.   We…

Taiwan Rongjin Lin, chairman of Center Ventures and Center Laboratories shares his story of how he revived Center Laboratories from the brink of bankruptcy and repositioned the pharmaceutical company to become one of Taiwan’s leading biotechnology capital funds. Lin goes on to share his view on the Taiwanese biotech investment landscape,…

Spain Luciano Conde, CEO, and Jose Luis Fumanal, VP of Sales and Marketing at Noventure, discuss how they set up the company in 2015 and their secret to achieving success in such a short period of time. Furthermore, they highlight what they look for in potential partners and their aspirations for…